Publications Journal for ImmunoTherapy of Cancer (October 1st 2021): Multicenter, double- blind, placebo- controlled trial of seviprotimut- L polyvalent melanoma vaccine in patients with post- resection melanoma at high risk of recurrence 2020 ASCO Poster Presentation: Final analysis of relapse-free survival in a multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine after resection of high-risk melanoma 2019 SITC Poster Presentation: A multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in post-resection melanoma patients at high risk of recurrence Changes in the Presence of Multiple Markers of Circulating Melanoma Cells Correlate with Clinical Outcome in Patients with Melanoma Cytoplasmic melanoma-associated antigen (CYT-MAA) serum level in patients with melanoma: A potential marker of response to immunotherapy? Double-Blind Trial of a Polyvalent, Shed-Antigen, Melanoma Vaccine Effect of DETOX as an adjuvant for melanoma vaccine HLA-Independent Heterogeneity of CD8+ T Cell Responses to MAGE-3, Melan A/Mart-1, gp100, Tyrosinase, MC1R, and TRP-2 in Vaccine-Treated Melanoma Patients Identification of immunogenic B16 melanoma-associated antigens Identification of melanoma cell surface antigens immunogenic in mice Immunogenicity and Tumor protective Activity of B16 Melanoma Vaccines Immunogenicity of a polyvalent melanoma antigen vaccine in humans> Improved Survival of Patients with Melanoma with Antibody Response to Immunization to a Polyvalent Melanoma Vaccine Induction of tumor-infiltrating lymphocytes in human malignant melanoma metastases by immunization to melanoma antigen vaccine Stimulation of CD8 T cell Responses to MAGE-3 and Melan A/MART-1 by immunization to a Polyvalent Melanoma Vaccine Vaccine-induced CD8 T-cell Responses to MAGE-3 Correlate with Clinical Outcome in Patients with Melanoma
